APA (7th ed.) Citation

Nandula, S. R., Jain, A., & Sen, S. (2025). Cardio-renal effect of dapagliflozin and dapagliflozin- saxagliptin combination on CD34 + ve hematopoietic stem cells (HSCs) and podocyte specific markers in type 2 diabetes (T2DM) subjects: A randomized trial. Stem cell research & therapy, 16(1), 28-18. https://doi.org/10.1186/s13287-025-04130-x

Chicago Style (17th ed.) Citation

Nandula, Seshagiri Rao, Arad Jain, and Sabyasachi Sen. "Cardio-renal Effect of Dapagliflozin and Dapagliflozin- Saxagliptin Combination on CD34 + ve Hematopoietic Stem Cells (HSCs) and Podocyte Specific Markers in Type 2 Diabetes (T2DM) Subjects: A Randomized Trial." Stem Cell Research & Therapy 16, no. 1 (2025): 28-18. https://doi.org/10.1186/s13287-025-04130-x.

MLA (9th ed.) Citation

Nandula, Seshagiri Rao, et al. "Cardio-renal Effect of Dapagliflozin and Dapagliflozin- Saxagliptin Combination on CD34 + ve Hematopoietic Stem Cells (HSCs) and Podocyte Specific Markers in Type 2 Diabetes (T2DM) Subjects: A Randomized Trial." Stem Cell Research & Therapy, vol. 16, no. 1, 2025, pp. 28-18, https://doi.org/10.1186/s13287-025-04130-x.